Last reviewed · How we verify
Diarrhea Secondary to Inflammatory Bowel Disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Imodium | loperamide | Johnson & Johnson (McNeil Consumer Healthcare) | Antidiarrheal (peripheral opioid agonist) | Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor | 1976-12-28 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Johnson & Johnson (McNeil Consumer Healthcare) · 1 drug in Diarrhea Secondary to Inflammatory Bowel Disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diarrhea Secondary to Inflammatory Bowel Disease:
- Diarrhea Secondary to Inflammatory Bowel Disease treatment updates — RSS
- Diarrhea Secondary to Inflammatory Bowel Disease treatment updates — Atom
- Diarrhea Secondary to Inflammatory Bowel Disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diarrhea Secondary to Inflammatory Bowel Disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diarrhea-secondary-to-inflammatory-bowel-disease. Accessed 2026-06-10.
Related
- Diarrhea Secondary to Inflammatory Bowel Disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing